Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 259186, 5 pages
Review Article

RP105-Negative B Cells in Systemic Lupus Erythematosus

Division of Rheumatology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan

Received 25 May 2011; Accepted 19 July 2011

Academic Editor: Anisur Rahman

Copyright © 2012 Syuichi Koarada and Yoshifumi Tada. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we discuss the RP105 biology and clinical significance in SLE.